Related Experiment Video
Updated: Jul 17, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment options for relapsed small-cell lung cancer
Hatem A Azim1, Apar Kishor Ganti
1Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Anti-Cancer Drugs
|February 1, 2007
Summary
Small-cell lung cancer is initially chemo-sensitive but often relapses, leading to poor survival. New targeted therapies show promise for salvage treatment, potentially improving outcomes for this aggressive malignancy.
Area of Science:
- Oncology
- Medical Research
Background:
- Small-cell lung cancer (SCLC) exhibits high initial response rates to chemotherapy (70-90%) but is characterized by frequent relapses and poor long-term survival.
- Chemotherapy provides a survival benefit over best supportive care, even in relapsed cases following platinum-based regimens.
Purpose of the Study:
- To review current and future salvage therapy options for small-cell lung cancer.
- To explore novel therapeutic targets and agents for treating relapsed SCLC.
Main Methods:
- Review of existing literature on SCLC salvage therapies.
- Analysis of emerging targeted agents and their biological targets (e.g., bcl-2, angiogenesis).
Main Results:
- Current salvage options include topotecan and combination regimens like cyclophosphamide, doxorubicin, and vincristine.
- Several novel agents targeting specific molecular pathways have shown early promise, necessitating further Phase III trials.
Conclusions:
- Despite initial chemo-sensitivity, SCLC salvage remains challenging due to common relapses.
- Advances in understanding SCLC biology are driving the development of targeted agents with the potential to significantly alter treatment paradigms.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...